Lipase inhibitors
View Patent ↗The present invention provides lipase inhibitory agents comprising a gallotannin or ellagitannin component(s) isolated from teas or Tellima grandiflora as well as foods and beverages and medicines containing said inhibitory agents. The present invention provides lipase inhibitory agents comprising at least one of compounds represented by formula I below: wherein R 1 , R 2 and R 3 independently represent H or a gallic acid residue, and R 4 and R 5 represent H or a gallic acid residue, or R 4 and R 5 together form an HHDP group represented by the formula below: provided that at least two of R 1 to R 5 represent a gallic acid residue or when all of R 1 , R 2 and R 3 are H, R 4 and R 5 together form the HHDP group; as well as foods and beverages and medicines containing said lipase inhibitory agents.
1. A method for suppressing absorption of dietary lipids and/or suppressing a rise of triglycerides in blood in a mammal, wherein the method comprises administering to the mammal a composition containing at least one of compounds represented by formula I below:
wherein R 1 , R 2 and R 3 independently represent H or a gallic acid residue, and R 4 and R 5 represent H or a gallic acid residue, or R 4 and R 5 together form an HHDP group represented by the formula below:
provided that at least two of R 1 to R 5 represent a gallic acid residue or when all of R 1 , R 2 and R 3 are H, R 4 and R 5 together form the HHDP group, wherein the compound(s) are capable of suppressing absorption of dietary lipids and/or suppressing a rise of triglycerides in blood in the mammal.
2. The method of claim 1 , wherein at least three of R 1 to R 5 are not H.
3. The method of claim 1 , wherein at least four of R 1 to R 5 are not H.
4. The method of claim 1 , wherein any of R 1 to R 5 are not H.
5. The method of claim 1 , wherein all of R 1 , R 2 and R 3 are a gallic acid residue, and R 4 and R 5 together form the HHDP group.
6. The method of claim 1 , wherein the composition is a food or beverage, or a pharmaceutical composition.
7. The method of claim 1 , wherein the composition contains at least one of the compounds in an amount of 0.1 mg or more per meal or 0.1 mg or more per dose.
8. The method of claim 7 , wherein the composition contains at least one of the compounds in an amount of 0.1 mg to 10 g per meal or 0.1 mg to 10 g per dose.
9. The method of claim 6 , wherein the composition is a food or beverage selected from the group consisting of tea drinks, soft drinks and health foods.
10. A method for inhibiting lipase activity in a mammal comprising administering to the mammal at least one of compounds represented by formula I below:
wherein R 1 , R 2 and R 3 independently represent H or a gallic acid residue, and R 4 and R 5 represent H or a gallic acid residue, or R 4 and R 5 together form an HHDP group represented by the formula below:
provided that at least two of R 1 to R 5 represent a gallic acid residue or when all of R 1 , R 2 and R 3 are H, R 4 and R 5 together form the HHDP group, wherein the compound(s) are capable of inhibiting lipase activity in the mammal.
11. The method of claim 10 , wherein at least three of R 1 to R 5 are not H.
12. The method of claim 10 , wherein at least four of R 1 to R 5 are not H.
13. The method of claim 10 , wherein any of R 1 to R 5 are not H.
14. The method of claim 10 , wherein all of R 1 , R 2 and R 3 are a gallic acid residue, and R 4 and R 5 together form the HHDP group.
15. A method for treating a disease or condition ameliorated by administering a lipase inhibitory agent in a mammal, wherein the method comprises administering to the mammal a composition containing at least one of compounds represented by formula I below:
wherein R 1 , R 2 and R 3 independently represent H or a gallic acid residue, and R 4 and R 5 represent H or a gallic acid residue, or R 4 and R 5 together form an HHDP group represented by the formula below:
provided that at least two of R 1 to R 5 represent a gallic acid residue or when all of R 1 , R 2 and R 3 are H, R 4 and R 5 together form the HHDP group, wherein the compound(s) are capable of treating the disease or condition ameliorated by administering a lipase inhibitory agent.
16. The method of claim 15 , wherein the disease or condition is one selected form the group consisting of obesity, diabetes, hyperlipidemia, hypertension, arteriosclerosis and hipertriglyceridemia.